AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00762528
Drug: Triclosan/Copolymer/fluoride toothpaste
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily usage
Trial: NCT02666976
Drug: Ilaprazole
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
Trial: NCT00762528
Drug: Sodium monofluorophosphate toothpaste
RxNorm normalized name: sodium monofluorophosphate Toothpaste
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice daily usage
Trial: NCT03022006
Drug: elbasvir, grazoprevir
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00466817
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
Trial: NCT02033993
Drug: Nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02033993
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01747993
Drug: Tamsulosin (0.4 mg/j)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (1 tablet / day for 6 days)
Trial: NCT01078454
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02696720
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01078454
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01078454
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02880345
Drug: PEMBROLIZUMAB
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00165620
Drug: Iomeprole
RxNorm normalized name: iomeprol
DrugBank: Iomeprol (DB11705)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01408615
Drug: corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 100 or 150 microgram single subcutaneous injection
Trial: NCT02545933
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
Trial: NCT02545933
Drug: Vorapaxar
RxNorm normalized name: Vorapaxar
DrugBank: Vorapaxar (DB09030)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vorapaxar will be administered at the dose of 2.5mg once daily
Trial: NCT02545933
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin will be administered at the dose of 81mg once daily
Trial: NCT02184897
Drug: lenograstim 10 microgram/kg/day
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02545933
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
Trial: NCT00655395
Drug: Laromustine (VNP40101M) and Ara-C
RxNorm normalized name: cytarabine
DrugBank: Laromustine (DB05817)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~2. Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion.
Trial: NCT02632032
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monitoring insulin therapy of campers based on their usual regimen (one of the following):~* premixed insulin in the morning and evening,~* premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,~* regular insulin in the morning and afternoon, and premixed insulin in the evening.~Education of campers on different aspects of diabetes care:~* monitoring of blood glucose~* injection of insulin~* adaptation of insulin doses according to blood glucose and during exercise~* correction of hypoglycemia~* dietary advice
Trial: NCT00226343
Drug: Depakote-ER
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02428062
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine 0.1-0.2 mg intravenous bolus
Trial: NCT00238199
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02428062
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A crystalloid fluid bolus is given intravenously (5-10 ml/kg)
Trial: NCT02428062
Drug: Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine 5-25 mg intravenous bolus
Trial: NCT00006032
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006032
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02148601
Drug: Vancomycin (before randomization)
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
Trial: NCT00006032
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01430910
Drug: Avibactam
RxNorm normalized name: Avibactam
DrugBank: Avibactam (DB09060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01430910
Drug: Ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04218513
Drug: Compound Edaravone Injection
RxNorm normalized name: edaravone Injection
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 min intravenous infusion
Trial: NCT03935321
Drug: NG-101
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 intrathecal bolus injections, each of 45mg
Trial: NCT04218513
Drug: Edaravone Injection
RxNorm normalized name: edaravone Injection
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 min intravenous infusion
Trial: NCT04218513
Drug: 2-Aminoethanesulfonic Acid Injection
RxNorm normalized name: Aminoethylsulfonic acid
DrugBank: Ethanesulfonic acid (DB03635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 min intravenous infusion
Trial: NCT04351620
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
Trial: NCT02265965
Drug: intravenous nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion at started at time of hysterotomy and stopped at neonate delivery
Trial: NCT02262780
Drug: Low dose of telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02262780
Drug: High dose of telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02262780
Drug: HCTZ
RxNorm normalized name: HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03288038
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03786380
Drug: Relamorelin 10 μg
RxNorm normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relamorelin 10 μg injected subcutaneously twice daily.
Trial: NCT00983372
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
Trial: NCT00983372
Drug: Diltiazem ER
RxNorm normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM ER]
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
Trial: NCT00983372
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
Trial: NCT04501250
Drug: Rinsulin NPH
RxNorm normalized name: INSULIN,NPH,BEEF
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection at a dose of 0.4 IU/kg
Trial: NCT04622566
Drug: Lenvatinib, Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After enrollment, patients receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 6 weeks; Lenvatinib 20mg orally once daily for 6 weeks. Patients conduct surgery within 1-4 weeks after the last dose of Pembrolizumab and Lenvatinib. After complete surgery, Pembrolizumab will be as adjuvant treatment for up to 15 cycles, 200mg IV on day 1 of every 21 day-cycles.
Trial: NCT00370617
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02175121
Drug: PF-06291874
RxNorm normalized name: PF-06291874
DrugBank: PF-06291874 (DB15065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 15 mg, once daily for 28 days
Trial: NCT02175121
Drug: PF-06291874
RxNorm normalized name: PF-06291874
DrugBank: PF-06291874 (DB15065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 35 mg, once daily for 28 days
Trial: NCT02175121
Drug: PF-06291874
RxNorm normalized name: PF-06291874
DrugBank: PF-06291874 (DB15065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 75 mg, once daily for 28 days
Trial: NCT02175121
Drug: PF-06291874
RxNorm normalized name: PF-06291874
DrugBank: PF-06291874 (DB15065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 150 mg, once daily for 28 days
Trial: NCT01349907
Drug: Asenapine
RxNorm normalized name: Asenapine
DrugBank: Asenapine (DB06216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
Trial: NCT00003653
Drug: cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented
Trial: NCT01588132
Drug: Anfibatide
RxNorm normalized name: Anfibatide
DrugBank: Anfibatide (DB15094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.~2. To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
Trial: NCT00432666
Drug: IncobotulinumtoxinA (Xeomin)
RxNorm normalized name: incobotulinumtoxinA Injection [Xeomin]
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection
Trial: NCT02199743
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Compare to haloperidol and perphenazine
Trial: NCT02199743
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compare to lurasidone
Trial: NCT02199743
Drug: Perphenazine
RxNorm normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compare to lurasidone
Trial: NCT01207934
Drug: low-dose leptin
RxNorm normalized name: ethinyl estradiol
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
Trial: NCT01207934
Drug: high-dose leptin
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
Trial: NCT00000484
Drug: Rauwolfia alkaloids
RxNorm normalized name: Rauwolfia alkaloids
DrugBank: Rauwolfia serpentina root (DB09363)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00739635
Drug: Neramexane mesylate
RxNorm normalized name: mesylate
DrugBank: Neramexane (DB04926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
Trial: NCT01960205
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg a day for 6 months
Trial: NCT01960205
Drug: saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg a day for 6 months
Trial: NCT01960205
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg three times a day for 6 months
Trial: NCT03507829
Drug: Insulin lispro, Humalog (Eli Lilly) in insulin pump
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro, Humalog (Eli Lilly) in insulin pump
Trial: NCT00906503
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
Trial: NCT03562169
Drug: Ixazomib, thalidomide, & dexamethasone (ITD) re-induction
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 - 6 ITD 28-day cycles as follows:~* Ixazomib 4mg capsule on days 1, 8 and 15~* Thalidomide 100mg capsule on days 1-28~* Dexamethasone 40mg tablets on days 1, 8, 15 and 22
Trial: NCT03562169
Drug: Conventional autologous stem cell transplant (ASCT-con)
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
Trial: NCT03562169
Drug: Augmented autologous stem cell transplant (ASCT-aug)
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
Trial: NCT03562169
Drug: ITD consolidation and ixazomib maintenance vs. No further therapy
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression.
Trial: NCT02985333
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 170 mg/m(2) IV over 3 h d1
Trial: NCT02985333
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20mg iv d1-4
Trial: NCT01779921
Drug: activated recombinant human factor VII
RxNorm normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Trial: NCT01779921
Drug: Plasma-derived FVII (LFB)
RxNorm normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Trial: NCT01779921
Drug: Prothrombin Complex conc. (PCC)
RxNorm normalized name: human prothrombin complex conc. (PCC) comb.1
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Trial: NCT00742911
Drug: Copper Gluconate
RxNorm normalized name: Copper Gluconate
DrugBank: Copper gluconate (DB11246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily
Trial: NCT00732069
Drug: Ramipril
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
Trial: NCT01835938
Drug: 1- Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Erlotinib 50 mg tablet by mouth every day for 14 days,~* Erlotinib 100 mg tablet by mouth every day for 14 days,~* Erlotinib 150 mg tablet by mouth every day for 14 days,
Trial: NCT02140281
Drug: Treatment B - AZD1722 followed by cefadroxil
RxNorm normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil